Skip to main content

US IDE Study of the Contour NEurovasCular System™ for IntraCranial Aneurysm Repair

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about US IDE Study of the Contour NEurovasCular System™ for IntraCranial Aneurysm Repair

DR REGISTRY: Prospective Observational Study of ADHF Patients With Insufficient Response to Diuretics

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about DR REGISTRY: Prospective Observational Study of ADHF Patients With Insufficient Response to Diuretics

Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab

To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)

Use of Tranexamic Acid in Reduction Mammoplasty

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Use of Tranexamic Acid in Reduction Mammoplasty

A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Diabetes Prevention Program Outcomes Study

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Diabetes Prevention Program Outcomes Study

Thiamine as a Renal Protective Agent in Septic Shock

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Thiamine as a Renal Protective Agent in Septic Shock

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 189
  • Page 190
  • Page 191
  • Page 192
  • Page 193
  • Page 194
  • Page 195
  • Page 196
  • Page 197
  • …
  • Next page Next
  • Last page Last
Subscribe to